{
    "id": 8051,
    "fullName": "B2M over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "B2M over exp indicates an over expression of the B2m protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 567,
        "geneSymbol": "B2M",
        "terms": [
            "B2M",
            "IMD43"
        ]
    },
    "variant": "over exp",
    "createDate": "06/22/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2470,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B2M over expressing multiple myeloma cells resistant to Velcade (bortezomib) demonstrated increased apoptotic activity when treated with a combination of Velcade (bortezomib) and anti-beta 2 microglobulin monoclonal antibodies (PMID: 25895124).",
            "molecularProfile": {
                "id": 7941,
                "profileName": "B2M over exp"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3141,
                    "pubMedId": 25895124,
                    "title": "Anti-\u03b2\u2082-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25895124"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7941,
            "profileName": "B2M over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}